Regeneron Pharmaceuticals

Quarterly Financials

Values in thousands 2024-12-31 2024-09-30 2024-06-30 2024-03-31
Revenue
$3,789,200
$3,720,700
$3,547,100
$3,145,000
Gross Profit
3,223,800
3,229,600
2,946,200
2,597,100
EBITDA
1,095,000
1,628,500
1,214,200
872,600
EBIT
968,600
1,506,800
1,093,500
758,500
Net Income
917,700
1,340,600
1,432,300
722,000
Net Change In Cash
3,789,200
3,720,700
3,547,100
3,145,000
Free Cash Flow
995,800
1,107,600
143,100
1,350,700
Cash
2,488,200
2,011,800
1,928,200
2,602,000
Basic Shares
113,800
116,200
115,400
115,100

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$14,202,000
$13,117,200
$12,172,900
$16,071,700
Gross Profit
12,231,500
12,233,500
10,612,500
13,634,200
EBITDA
5,318,000
4,047,100
5,335,400
9,281,000
EBIT
4,835,100
4,047,100
4,994,000
8,994,800
Net Income
4,412,600
3,953,600
4,338,400
8,075,300
Net Change In Cash
14,202,000
13,117,200
12,172,900
16,071,700
Cost of Revenue
221,300
690,800
Free Cash Flow
3,664,600
3,667,600
4,424,800
6,529,400
Cash
2,488,200
2,730,000
3,105,900
2,885,600
Basic Shares
115,100
113,700
113,500
112,200

Earnings Calls

Quarter EPS
2024-12-31
$12.07
2024-09-30
$12.46
2024-06-30
$11.56
2024-03-31
$9.55